Trial Profile
PHASE 1/2 OPEN-LABEL STUDY OF PF-06747775 (EPIDERMAL GROWTH FACTOR RECEPTOR T790M INHIBITOR) IN PATIENTS WITH ADVANCED EPIDERMAL GROWTH FACTOR RECEPTOR MUTANT (DEL 19 OR L858R ± T790M) NON-SMALL CELL LUNG CANCER
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 27 Jul 2022
Price :
$35
*
At a glance
- Drugs Mavelertinib (Primary) ; Avelumab; Palbociclib
- Indications Non-small cell lung cancer
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Pfizer
- 01 Jul 2022 Results reporting safety data published in the Expert Opinion on Investigational Drugs
- 27 Aug 2020 Status changed from completed to discontinued.
- 18 Jun 2020 Status changed from active, no longer recruiting to completed.